Creative Planning
LUCD icon

Creative Planning’s Lucid Diagnostics LUCD Stock Holding History

Creative Planning’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6K Buy
14,420
+2,553
+22% +$3.25K ﹤0.01% 4053
2025
Q4 		$12.9K Sell
11,867
-4
-0% -$4 ﹤0.01% 3864
2025
Q3 		$12K Buy
11,871
+18
+0.2% +$20 ﹤0.01% 3835
2025
Q2 		$13.6K Hold
11,853
– – ﹤0.01% 3608
2025
Q1 		$17.7K Hold
11,853
– – ﹤0.01% 3410
2024
Q4 		$9.7K Buy
+11,853
New +$10.5K ﹤0.01% 3384

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Creative Planning's LUCD Position: Q1 2026 in Review

Creative Planning increased its Lucid Diagnostics (LUCD) stake by 22% in Q1 2026, buying an estimated $3.25K and bringing the position to 14,420 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4053.

Creative Planning first reported a position in LUCD in Q4 2024 and has held it in 6 quarters since. The position peaked at $17.7K in Q1 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Creative Planning held 14,420 shares of Lucid Diagnostics worth $16.6K as of Q1 2026.
  • Creative Planning bought 2,553 Lucid Diagnostics shares in Q1 2026, an estimated $3.25K.
  • Lucid Diagnostics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #4053 holding.
  • Creative Planning first reported a position in Lucid Diagnostics in Q4 2024 and has held it in 6 quarters since.
  • Creative Planning's Lucid Diagnostics position peaked at $17.7K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.